Trial Profile
A Randomized, Double-masked, Multicenter, Laser Controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Monotherapy in Patients With Visual Impairment Due to Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Feb 2014
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms REVEAL
- Sponsors Novartis
- 25 Feb 2014 New trial record
- 21 Feb 2014 Lucentis [ranibizumab] was approved by Japanese regulatory bodies for the treatment of diabetic macular oedema based on results from the REVEAL trial, according to a Novartis media release.